Loading...

PerCP/Cyanine5.5 anti-human HLA-DR Antibody

Pricing & Availability
Clone
L243 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class II, MHC class II
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
L243_PerCPCyanine55_HLA-DR_Antibody_103118
Human peripheral blood lymphocytes were stained with CD19 APC and HLA-DR (clone L243) PerCP/Cyanine5.5 (left), or mouse IgG2a, κ PerCP/Cyanine5.5 isotype control (right).
  • L243_PerCPCyanine55_HLA-DR_Antibody_103118
    Human peripheral blood lymphocytes were stained with CD19 APC and HLA-DR (clone L243) PerCP/Cyanine5.5 (left), or mouse IgG2a, κ PerCP/Cyanine5.5 isotype control (right).
See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
307629 25 tests 141€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
307630 100 tests 306€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.

Product Details
Technical data sheet

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the aß heterodimer.19

Additional reported applications (for the relevant formats) include: immunoprecipitation8, Western blotting8, in vitro blocking of mixed lymphocyte reactions9,10, depeletion of MHC class II cells7, immunohistochemical staining of acetone-fixed frozen sections4,5, and spatial biology (IBEX)21,22. For sensitive functional assays, we recommend using the Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 307648, 307665 - 307669).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Brodsky F. 1984. Immunogenetics 19:179.
  2. Robbins P, et al. 1987. Human Immunol. 18:301.
  3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
  4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
  5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
  6. Zipf T, et al. 1981. Cancer Res. 41:4786.
  7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
  8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
  9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
  10. Wang RF, et al. 1999. Science 284:1351. (Block)
  11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
  12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
  13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
  15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
  18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
  19. Moro M, et al. 2005. BMC Immunol. 6:24.
  20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
  21. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  22. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  2. Cavrois M, et al. 2019. PLoS One. 14:e0221181. PubMed
  3. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
  4. Nilsson JS, et al. 2019. Oncol Lett. 2.484027778. PubMed
  5. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  6. Zhang D, et al. 2020. Oncoimmunology. 9:1744921. PubMed
  7. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  8. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  9. Cytlak U, et al. 2020. Immunity. 53(2):353-370. PubMed
  10. Levin M, et al. 2013. J Immunol. 191:551. PubMed
  11. Ohlsson S, et al. 2014. Clin Immunol. 152:10. PubMed
  12. Fredriksson K, et al. 2014. J Immunol. 192:4497. PubMed
  13. Weinberg A, et al. 2015. PLoS One. 10:122431. PubMed
  14. Mottok A, et al. 2015. Cell Rep. 13:1418-31. PubMed
  15. D’Abramo A, et al. 2016. PLoS One. 11: 0149601. PubMed
  16. Kanderova V, et al. 2016. Mol Cell Proteomics. 15: 1246-1261. PubMed
  17. Iannetta M, et al. 2016. PLoS One. 11: 0160277. PubMed
  18. Price A, et al. 2016. Proc Natl Acad Sci U S A. 113: 10678 - 1068. PubMed
  19. Walker‐Sperling VE et al. 2017. EBioMedicine. 16:141-149 . PubMed
  20. Oh DY, et al. 2020. Cell. 181:1612. PubMed
  21. Parker R, et al. 2021. Cell Reports. 35(8):109179. PubMed
  22. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  23. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  24. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  25. Rha MS, et al. 2021. Immunity. 54:44. PubMed
  26. Moreno-Fernandez ME, et al. 2021. STAR Protoc. 2:100937. PubMed
  27. Masuda N, et al. 2021. BMC Cancer. 21:1269. PubMed
  28. Luo Y, et al. 2021. Front Immunol. 12:761209. PubMed
  29. Pi J, et al. 2022. J Nanobiotechnology. 20:36. PubMed
  30. Elston L, et al. 2020. Br J Haematol. 188:872. PubMed
  31. Port JR, et al. 2020. J Virol. 94:. PubMed
  32. Domanska D, et al. 2022. J Exp Med. 219:. PubMed
  33. Ireland RE, et al. 2022. Viruses. 14:. PubMed
  34. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Salumets A, et al. 2022. Aging Cell. 21:e13607. PubMed
  36. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  37. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  38. Xu Q, et al. 2022. Front Med (Lausanne). 9:940554. PubMed
RRID
AB_893575 (BioLegend Cat. No. 307629)
AB_893567 (BioLegend Cat. No. 307630)

Antigen Details

Structure
Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
Distribution

B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs

Function
Peptide presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.

Gene ID
3122 View all products for this Gene ID 3123 View all products for this Gene ID
UniProt
View information about HLA-DR on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Go To Top Version: 3    Revision Date: 10.31.2018

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account